Positive Phase III Results May Mean Big Payday for Ariad
Top-line results from a Phase III trial showed that Ariad Pharmaceuticals Inc.'s ridaforolimus has promise as a treatment for metastatic soft-tissue or bone sarcoma. In the trial designated SUCCEED, carried out under a special protocol assessment granted by the FDA, there was a 28 percent reduction in the risk of progression compared to placebo, and a 21 percent (or 3.1 week) improvement in progression-free survival.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter